http://rdf.ncbi.nlm.nih.gov/pubchem/patent/ES-2422302-T3
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_7e245040050dcffd5bc242ab2cd486b6 |
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-106 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-158 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q1-6886 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-574 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12P19-34 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P43-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-09 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-513 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12Q- http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-574 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12Q1-68 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-50 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-282 |
| filingDate | 2001-11-09-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2013-09-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_2aaf33001af051caa04188d15f400499 |
| publicationDate | 2013-09-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | ES-2422302-T3 |
| titleOfInvention | Method to determine a chemotherapeutic regimen based on ERCC1 and TS expression |
| abstract | A method of determining a chemotherapeutic regimen comprising 5-fluoroacyl, oxaliplatin, or a combination thereof for the treatment of a tumor in a patient, comprising: (a) fixing a tumor sample and embedding the paraffin-fixed sample; (b) isolating the mRNA from the paraffin-embedded fixed tumor sample by heating the sample soaked in a solution comprising an effective concentration of a chaotropic compound at a temperature in the range of from about 75 to about 100 ° C over a period of time from about 120 minutes to recovering said mRNA from said chaotropic solution; (c) subjecting the mRNA to amplification using a pair of oligonucleotide primers that hybridize under stringent conditions to a region of the ERCC1 gene and comprises SEQ ID NO: 1 or at least 80% identical oligonucleotide primer, and SEQ ID NO: 2 or an oligonucleotide primer at least 80% identical thereto, and a pair of oligonucleotide primers that rigorously hydrate a region of the TS gene and comprises SEQ ID NO: 3 or an oligonucleotide primer at least 80% identical thereto, and SEQ ID NO: 4 or an oligonucleotide primer at least 80% identical thereto, to obtain an amplified sample of ERCC1 and an amplified sample of TS; (d) determining the amount of TS and ERCC1 mRNA in the amplified sample; (e) comparing the amount of TS and ERCC1 mRNA from step (d) to an amount of mRNA from an internal control gene; and (f) determining a chemotherapeutic regimen comprising 5-fluorouracil, oxaliplatin, or a combination thereof, based on the amount of TS and / or ERCC1 mRNA in the amplified sample and the threshold level for expression of the TS gene and / or ERCC1. |
| priorityDate | 2000-12-01-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 36.